La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

IRRAS Bilan de santé

Santé financière contrôle des critères 4/6

IRRAS possède un total de capitaux propres de SEK43.1M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK96.5M et de SEK53.4M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 13.10m
Fonds propres	SEK 43.10m
Total du passif	SEK 53.40m
Total des actifs	SEK 96.50m

Mises à jour récentes de la santé financière

Recent updates

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

Dec 10

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Jan 19

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Sep 22

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Apr 07

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de IRRAS ( SEK68.7M ) dépassent ses passifs à court terme ( SEK53.3M ).

Passif à long terme: Les actifs à court terme de IRRAS ( SEK68.7M ) dépassent ses passifs à long terme ( SEK100.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: IRRAS est sans dette.

Réduire la dette: IRRAS n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: IRRAS dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: IRRAS dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 12.1 % chaque année

IRRAS Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00

New 90-day high: kr6.98

Analysts increase revenue estimates to kr27.5m

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines